Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (NCT02414269)
A Phase I/II Clinical Trial of Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this Phase I study is to test the safety of different doses of specially prepared immune cells (called "T cells") collected from blood. The Investigators want to find a safe dose of these modified T cells for patients who have malignant pleural disease. They want to find out what effects these T cells have on the patient and the cancer (MPD). Phase 2 part of the study, the investigators will test the dose in combination with another drug, pembrolizumab, to see what effects the study treatment has on malignant pleural mesothelioma.
Who can join: Review the eligibility criteria below.
Location: Memorial Sloan Kettering Basking Ridge (Consent and Follow-Up) — Basking Ridge, New Jersey
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- Memorial Sloan Kettering Basking Ridge (Consent and Follow-Up) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Consent and Follow-Up) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Consent and Follow-Up) — Montvale, New Jersey
- Memorial Sloan Kettering Commack (Consent and Follow-Up) — Commack, New York
- Memorial Sloan Kettering Westchester (Consent and Follow-Up) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (Consent and Follow-Up) — New York, New York
📞 Contact the Study Coordinator
Phone: (800) 525-2225
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Malignant Pleural Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.